DGAP-News: IncellDx Signs Agreement With Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test
(firmenpresse) - IncellDx
29.10.2013 13:30
---------------------------------------------------------------------------
MENLO PARK, Calif., 2013-10-29 13:30 CET (GLOBE NEWSWIRE) --
IncellDx, Inc. announced today that they have entered into an agreement with
Bristol-Myers Squibb Company (NYSE:BMY) related to the development of an assay
for potential application in a molecular companion diagnostic intended to
identify patients likely to benefit from treatment with a Bristol-Myers Squibb
drug that is currently under development.
The test will be based upon a modification of IncellDx's quantitative
InCellCept assay, a cell-based instrument capable of quantifying molecular
biomarkers inside intact cells. This allows protein and gene expression to be
measured by distinct cell type, which aids both diagnosis and disease
localization. If successful, the companies anticipate extending the
relationship into development of a molecular companion diagnostic in which the
assay would be used to determine phenotypic susceptibility of patients' disease
prior to treatment.
This collaboration with Bristol-Myers Squibb highlights IncellDx's commitment
to precision diagnostics and personalized medicine. 'The agreement highlights
the breadth of IncellDx's novel cellular multiplexing molecular technology,'
commented Bruce Patterson, MD, CEO of IncellDx.
Financial terms of the agreement were not disclosed.
About IncellDx Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection
and monitoring of life threatening diseases such as cervical cancer, breast
cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more
information, please visit www.incelldx.com.
Eric Hass
IncellDx, Inc.
(T) +1.650.777.7630
News Source: NASDAQ OMX
29.10.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: IncellDx
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902652257
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
incelldx-signs-agreement-with-bristol
myers-squibb-related-to-the-development-of-an-assay-for-a-companion-diagnostic-test
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2013 - 13:30 Uhr
Sprache: Deutsch
News-ID 310257
Anzahl Zeichen: 2190
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: IncellDx Signs Agreement With Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test"
steht unter der journalistisch-redaktionellen Verantwortung von
IncellDx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
